Orion Corporation: Managers’ transactions – Veli-Matti Mattila

Group 1 - Orion Corporation has received a disclosure regarding transactions made by its board member Veli-Matti Mattila under Market Abuse Regulation [1] - The transaction involved the receipt of a share-based incentive, with a volume of 830 shares at a unit price of 0 EUR [1] - The aggregated transaction also reflects a volume of 830 shares with a volume weighted average price of 0 EUR [1] Group 2 - Orion Corporation is a Nordic pharmaceutical company with over a hundred years of experience, focusing on human and veterinary pharmaceuticals [2] - In 2024, Orion's net sales reached EUR 1,542 million, and the company employed approximately 3,700 professionals globally [2] - Orion's core therapy areas in pharmaceutical R&D include oncology and pain, with proprietary products developed for treating cancer, neurological diseases, and respiratory diseases [2]